Allogeneic Bone Marrow Transplantation in Patients with Myelodysplastic Syndromes

References

• Doll D. C., List A. F. Myelodysplastic syndromes. Western J. Med. 1989; 151: 161–167
   PubMedGoogle Scholar
• Anastasi J., Feng J., Le Beau M. M., Larson R. A., Rowley J. D., Vardiman J. W. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: Lineage, response to growth factor therapy, and clone expansion. Blood 1993; 81: 1580–1585
   PubMed Web of Science ®Google Scholar
• Janssen J. W., Buschle M., Layton M., Drexler H. G., Lyons J., van den Berghe H., Heimpel H., Kubanek B., Kleihauer E., Mufti G. J., et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 1989; 73: 248–254
   PubMed Web of Science ®Google Scholar
• Tsukamoto N., Morita K., Maehara T., Okamoto K., Karasawa M., Omine M., Naruse T. Clonality in myelodysplastic syndromes: Demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms. Br. J. Haematol. 1993; 83: 589–594
   PubMed Web of Science ®Google Scholar
• Culligan D. J., Cachia P., Whittaker J., Jacobs A., Padua R. A. Clonal lymphocytes are detectable in only some cases of MDS. Br. J. Haematol. 1992; 81: 346–352
   PubMed Web of Science ®Google Scholar
• van Kamp H., Fibbe W. E., Jansen R. P., van der Keur M., de Graaff E., Willemze R., Landegent J. E. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: Analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood 1992; 80: 1774–1780
   PubMed Web of Science ®Google Scholar
• Kere J., Ruutu T., Lahtinen R., de la Chapelle A. Molecular characterization of chromosome 7 long arm deletions in myeloid disorders. Blood 1987; 70: 1349–1353
   PubMed Web of Science ®Google Scholar
• Cheson B. D. The myelodysplastic syndromes: Current approaches to therapy. Ann. Intern. Med. 1990; 112: 932–941
   PubMed Web of Science ®Google Scholar
• Vallespi T., Torrabadella M., Julia A., Irriguible D., Jaen A., Acebedo G., Triginer J. Myelodysplastic syndromes: A study of 101 cases according to the FAB classification. Br. J. Haematol. 1985; 61: 83–92
   PubMed Web of Science ®Google Scholar
• Vandermolen L., Rice L., Rose M. A., Lynch E. C. Ringed sideroblasts in primary myelodysplasia. Leukemic propensity and prognostic factors. Arch. Intern. Med. 1988; 148: 653–656
   PubMed Web of Science ®Google Scholar
• Jacobs R. H., Cornbleet M. A., Vardiman J. W., Larson R. A., Le Beau M. M., Rowley J. D. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986; 67: 1765–1772
   PubMed Web of Science ®Google Scholar
• Andreeff M., Stone R., Michaeli J., Young C. W., Tong W. P., Sogoloff H., Ervin T., Kufe D., Rifkind R. A., Marks P. A. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 1992; 80: 2604–2609
   PubMed Web of Science ®Google Scholar
• Ohno R., Naoe T., Hirano M., Kobayashi M., Hirai H., Tubaki K., Oh H. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood 1993; 81: 1152–1154
   PubMed Web of Science ®Google Scholar
• Besa E. C., Abraham J. L., Bartholomew M. J., Hyzinski M., Nowell P. C. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-to-copherol. Am. J. Med. 1990; 89: 739–747
   PubMed Web of Science ®Google Scholar
• Picozzi V. J., Jr., Swanson G. F., Morgan R., Hecht F., Greenberg P. L. 13-cis retinoic acid treatment for myelodysplastic syndromes. J. Clin. Oncol. 1986; 4: 589–595
   PubMed Web of Science ®Google Scholar
• Schuster M. W. Will cytokines alter the treatment of myelodysplastic syndrome?. Am. J. Med. Sci. 1993; 305: 72–78
   PubMed Web of Science ®Google Scholar
• Gradishar W. J., Le Beau M. M., O'Laughlin R., Vardiman J. W., Larson R. A. Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood 1992; 80: 2463–2470
   PubMed Web of Science ®Google Scholar
• Negrin R. S., Haeuber D. H., Nagler A., Olds L. C., Donlon T., Souza L. M., Greenberg P. L. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. Ann. Intern. Med. 1989; 110: 976–984
   PubMed Web of Science ®Google Scholar
• Kobayashi Y., Okabe T., Ozawa K., Chiba S., Hino M., Miyazono K., Urabe A., Takaku F. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report. Am. J. Med. 1989; 86: 178–182
   PubMed Web of Science ®Google Scholar
• Ganser A., Volkers B., Greher J., Ottmann O. G., Walther F., Becher R., Bergmann L., Schulz G., Hoelzer D. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes-a phase I/II trial. Blood 1989; 73: 31–37
   PubMed Web of Science ®Google Scholar
• Antin J. H., Smith B. R., Holmes W., Rosenthal D. S. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988; 72: 705–713
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S., Keating M., Le Maistre A., Hittelman W. N., Mc Credie K., Trujillo J. M., Broxmeyer H. E., Hen-Ney C., Gutterman J. U. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N. Engl. J. Med. 1987; 317: 1545–1552
   PubMed Web of Science ®Google Scholar
• Ganser A., Hoelzer D. Clinical course of myelodysplastic syndromes. Hematol. Oncol. Clin. N. Am. 1992; 6(3)607–618
   PubMed Web of Science ®Google Scholar
• Mangi M. H., Mufti G. J. Primary myelodysplastic syndromes: Diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 1992; 79: 198–205
   PubMed Web of Science ®Google Scholar
• Mufti G. J. A guide to risk assessment in primary myelodysplastic syndrome. Hematol. Oncol. Clin. N. Am. 1992; 6(3)587–606
   PubMed Web of Science ®Google Scholar
• Raymakers R., De Witte T., Joziasse J., Van der Lely N., Boezeman J., Haanen C. In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukaemia. Br. J. Haematol. 1991; 78: 35–41
   PubMed Web of Science ®Google Scholar
• van der Weide M., Sizoo W., Nauta J. J., Krefft J., Langenhuijsen M. M. Myelodysplastic syndromes: Analysis of clinical and prognostic features in 96 patients. Eur. J. Haematol. 1988; 41: 115–122
   PubMed Web of Science ®Google Scholar
• Noel P., Tefferi A., Pierre R. V., Jenkins R. B., De-Wald G. W. Karyotypic analysis in primary myelodysplastic syndromes. Blood Rev. 1993; 7: 10–18
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V., Karanes C., Uberti J., Lum L. G., de Planque M. M., Schultz K. R., Cronin S., Dan M. E., Mohamed A., Hussein M., et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 1993; 81: 2194–2199
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V., Karanes C., Lum L. G., Uberti J., Dan M. E., de Planque M. M., Schultz K. R., Cronin S., Leisz M. C., Mohamed A., et al. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Bone Marrow Transplant 1992; 9: 49–55
   PubMed Web of Science ®Google Scholar
• Santos G. W., Tutschka P. J., Brookmeyer R., Saral R., Beschorner W. E., Bias W. B., Braine H. G., Burns W. H., Eifenbein G. J., Kaizer H., Mellits D., Sensenbrenner L. L., Stuart R. K., Yeager A. M. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N. Engl. J. Med. 1983; 309: 1347–1353
   PubMed Web of Science ®Google Scholar
• Vassal G., Gouyette A., Hartmann O., Pico J. L., Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother. Pharmocol. 1989; 24: 386–390
   PubMed Web of Science ®Google Scholar
• Anderson J. E., Appelbaum F. R., Fisher L. D., Schoch G., Shulman H., Anasetti C., Bensinger W. I., Bryant E., Buckner C. D., Doney K., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677–681
   PubMed Web of Science ®Google Scholar
• Kernan N. A., Bartsch G., Ash R. C., Beatty P. G., Champlin R., Filipovich A., Gajewski J., Hansen J. A., Henslee-Downey J., Mc Cullough J., et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N. Engl. J. Med. 1993; 328: 593–602
   PubMed Web of Science ®Google Scholar
• De Witte T., Zwaan F., Hermans J., Vernant J., Kolb H., Vossen J., Lonnqvist B., Beelen D., Ferrant A., Gmur J., et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: A survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br. J. Haematol. 1990; 74: 151–155
   PubMed Web of Science ®Google Scholar
• Longmore G., Guinan E. C., Weinstein H. J., Gelber R. D., Rappeport J. M., Antin J. H. Bone marrow transplantation for myelodysplasia and secondary acute non-lymphoblastic leukemia. JCO 1990; 8: 1707–1714
   PubMed Web of Science ®Google Scholar
• O'Donnell M. R., Nademanee A. P., Snyder D. S., Schmidt G. M., Parker P. M., Bierman P. J., Fahey J. L., Stein A. S., Krance R. A., Stock A. D., Forman S. J., Blume K. G. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. JCO 1987; 5: 1822–1826
   PubMed Web of Science ®Google Scholar
• Nevill T. J., Shepard J. D., Reece D. E., Barnett M. J., Nantel S. H., Klingemann H.-G., Phillips G. L. Treatment of myelodysplastic syndrome with busulfan-cyclo-phosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 1992; 10: 445–450
   PubMed Web of Science ®Google Scholar
• Tutschka P. J., Copelan E. A., Klein J. P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–1388
   PubMed Web of Science ®Google Scholar